Regeneron Pharmaceuticals, Inc.

REGN

$113.80B

Large Cap

NASDAQPharmaceutical PreparationsPharmaceuticals🇺🇸North AmericaTARRYTOWN15.2K employees

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Website

Drugs in Pipeline

100

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jan 28, 2026

Market Overview

Stock performance and market intelligence

Catalyst Timeline

30 upcoming, 2 past

Phase 2Next

REGN7544 Phase 2 Results Expected

Jan 28, 2026REGN754481

Primary completion for REGN7544 trial (NCT06593600) in Postural Orthostatic Tachycardia Syndrome (POTS)

Source

Phase 2

Sarilumab Phase 2 Results Expected

Feb 1, 2026Sarilumab890

Primary completion for Sarilumab trial (NCT03564340) in Recurrent Ovarian Cancer

Source

Phase 2

Tocilizumab Phase 2 Results Expected

Feb 1, 2026Tocilizumab890

Primary completion for Tocilizumab trial (NCT03564340) in Recurrent Ovarian Cancer

Source

Phase 2

Cemiplimab Phase 2 Results Expected

Feb 1, 2026cemiplimab890

Primary completion for Cemiplimab trial (NCT03564340) in Recurrent Ovarian Cancer

Source

Phase 2

Placebo Phase 2 Results Expected

Feb 18, 2026Dupilumab22

Primary completion for Placebo trial (NCT06593600) in Postural Orthostatic Tachycardia Syndrome (POTS)

Source

⭐Phase 3

Cemiplimab Phase 3 Results Expected

Mar 16, 2026cemiplimab1,546

Primary completion for Cemiplimab trial (NCT05352672) in Melanoma

Source

⭐Phase 3

Fianlimab Phase 3 Results Expected

Mar 16, 2026Fianlimab1,546

Primary completion for Fianlimab trial (NCT05352672) in Melanoma

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Mar 16, 2026Dupilumab1,546

Primary completion for Placebo trial (NCT05352672) in Melanoma

Source

⭐Phase 3

Pembrolizumab Phase 3 Results Expected

Mar 16, 2026Pembrolizumab1,546

Primary completion for Pembrolizumab trial (NCT05352672) in Melanoma

Source

Phase 2

Carboplatin Phase 2 Results Expected

Apr 17, 2026Carboplatin195

Primary completion for Carboplatin trial (NCT06161441) in Resectable Non-small Cell Lung Cancer

Source

Phase 2

Cemiplimab Phase 2 Results Expected

May 13, 2026cemiplimab180

Primary completion for Cemiplimab trial (NCT06161441) in Resectable Non-small Cell Lung Cancer

Source

Phase 2

Pemetrexed Phase 2 Results Expected

May 13, 2026Pemetrexed180

Primary completion for Pemetrexed trial (NCT06161441) in Resectable Non-small Cell Lung Cancer

Source

Phase 2

Placebo Phase 2 Results Expected

May 13, 2026Dupilumab180

Primary completion for Placebo trial (NCT06161441) in Resectable Non-small Cell Lung Cancer

Source

Phase 2

Fianlimab Phase 2 Results Expected

May 13, 2026Fianlimab180

Primary completion for Fianlimab trial (NCT06161441) in Resectable Non-small Cell Lung Cancer

Source

Phase 2

Trevogrumab-Part A Phase 2 Results Expected

May 18, 2026Trevogrumab-Part A1,005

Primary completion for Trevogrumab-Part A trial (NCT06299098) in Obesity

Source

Phase 2

Garetosmab Phase 2 Results Expected

May 18, 2026Garetosmab1,005

Primary completion for Garetosmab trial (NCT06299098) in Obesity

Source

Phase 2

REGN9933 Phase 2 Results Expected

Jun 1, 2026REGN9933195

Primary completion for REGN9933 trial (NCT06299111) in Venous Thromboembolism

Source

Phase 2

REGN7508 Phase 2 Results Expected

Jun 1, 2026REGN7508195

Primary completion for REGN7508 trial (NCT06299111) in Venous Thromboembolism

Source

Phase 2

Placebo Phase 2 Results Expected

Jun 8, 2026Alirocumab195

Primary completion for Placebo trial (NCT06161441) in Resectable Non-small Cell Lung Cancer

Source

Phase 2

Odronextamab Phase 2 Results Expected

Jul 6, 2026Odronextamab515

Primary completion for Odronextamab trial (NCT03888105) in B-cell Non-Hodgkin Lymphoma (B-NHL)

Source

⭐Phase 3

mibavademab Phase 3 Results Expected

Jul 14, 2026mibavademab9

Primary completion for mibavademab trial (NCT06548100) in Generalized Lipodystrophy

Source

Phase 2

PB Phase 2 Results Expected

Jul 23, 2026PB76

Primary completion for PB trial (NCT06608901) in Sepsis-Induced Hypotension

Source

Phase 2

REGN7544 Phase 2 Results Expected

Jul 23, 2026REGN754476

Primary completion for REGN7544 trial (NCT06608901) in Sepsis-Induced Hypotension

Source

Phase 2

REGN7075 Phase 2 Results Expected

Aug 19, 2026REGN7075933

Primary completion for REGN7075 trial (NCT04626635) in Advanced Solid Tumors

Source

⭐Phase 3

Dupilumab Phase 3 Results Expected

Oct 7, 2026Dupilumab880

Primary completion for Dupilumab trial (NCT02612454) in Atopic Dermatitis

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Nov 3, 2026Dupilumab415

Primary completion for Placebo trial (NCT03969004) in Cutaneous Squamous Cell Carcinoma

Source

⭐Phase 3

Cemiplimab Phase 3 Results Expected

Nov 3, 2026cemiplimab415

Primary completion for Cemiplimab trial (NCT03969004) in Cutaneous Squamous Cell Carcinoma

Source

Phase 2

Sarilumab Phase 2 Results Expected

Jan 14, 2027Sarilumab370

Primary completion for Sarilumab trial (NCT05125016) in Metastatic Castration-resistant Prostate Cancer

Source

Phase 2

REGN5678 Phase 2 Results Expected

Jan 14, 2027REGN5678370

Primary completion for REGN5678 trial (NCT05125016) in Metastatic Castration-resistant Prostate Cancer

Source

Phase 2

Cemiplimab Phase 2 Results Expected

Jan 14, 2027cemiplimab370

Primary completion for Cemiplimab trial (NCT05125016) in Metastatic Castration-resistant Prostate Cancer

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Dupixent

Dupilumab

Approved

Atopic Dermatitis

Acetylsalicylic Acid (ASA)

Drug Name	Phase	Indication	Designations
Dupixent Dupilumab	Approved	Atopic Dermatitis	-
Acetylsalicylic Acid (ASA)	Phase 3	Symptomatic Venous Thromboembolism (VTE)	-
Libtayo Cemiplimab	Phase 3	Non-Small Cell Lung Cancer	Fast Track
Odronextamab	Phase 3	Diffuse Large B-cell Lymphoma (DLBCL)	-
aflibercept	Phase 3	Diabetic Macular Edema	-
Cemdisiran	Phase 3	Paroxysmal Nocturnal Hemoglobinuria	-
Rilonacept	Phase 3	Gout	-
cemiplimab	Phase 3	Advanced Cutaneous Squamous Cell Carcinoma	-
Fasinumab	Phase 3	Osteoarthritis of the Knee or Hip	-
Fianlimab	Phase 3	Melanoma	-
Pozelimab	Phase 3	CD55-deficient Protein-losing Enteropathy	-
Pemetrexed	Phase 3	Non-small Cell Lung Cancer	-
mibavademab	Phase 3	Generalized Lipodystrophy	-
Rosuvastatin	Phase 3	Hypercholesterolemia	-
Rilonacept 80 mg	Phase 3	Intercritical Gout	-
REGN7508	Phase 3	Venous Thromboembolism (VTE)	-
Intravitreal Aflibercept Injection 2mg	Phase 3	Neovascular Age-related Macular Degeneration	-
Sarilumab	Phase 3	COVID-19	-
Carboplatin	Phase 3	Resectable Non-small Cell Lung Cancer	-
REGN10933 + REGN10987	Phase 3	Healthy Participants	-
Gemcitabine	Phase 3	Carcinoma，Non-Small-Cell Lung	-
Dexamethasone	Phase 3	B-Cell Non-Hodgkin Lymphoma (B-NHL)	-
Intravitreal aflibercept injection [IAI]	Phase 3	Nonproliferative Diabetic Retinopathy	-
REGN5713	Phase 3	Allergic Rhinitis	-
Indomethacin	Phase 3	Acute Gout Flare	-
aflibercept 8 mg PFS	Phase 3	Diabetic Macular Edema (DME)	-
Investigator Choice (IC) Chemotherapy	Phase 3	Squamous Cell Carcinoma (SCC)	-
Suptavumab 30 mg/kg	Phase 3	Respiratory Syncytial Virus Infections	-
Elotuzumab	Phase 3	Relapsed Refractory Multiple Myeloma (RRMM)	-
Garetosmab	Phase 3	Fibrodysplasia Ossificans Progressiva	-
Evinacumab	Phase 3	Hypercholesterolemia	-
Linvoseltamab	Phase 3	Monoclonal Gammopathy of Undetermined Significance (MGUS)	-
Atorvastatin	Phase 3	Hypercholesterolemia	-
Naproxen	Phase 3	Osteoarthritis, Knee	-
Ravulizumab	Phase 3	Paroxysmal Nocturnal Hemoglobinuria	-
rilonacept 160 mg	Phase 3	Familial Cold Autoinflammatory Syndrome (FCAS)	-
VEGF Trap-Eye 2.0mg	Phase 3	Macular Edema Secondary to Central Retinal Vein Occlusion	-
ranibizumab	Phase 3	Macular Degeneration	-
Oral corticosteroids (OCS)	Phase 3	Bullous Pemphigoid	-
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)	Phase 3	Diabetic Macular Edema	-
REGN1908	Phase 3	Allergic Conjunctivitis	-
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)	Phase 3	Branch Retinal Vein Occlusion	-
Aflibercept 8 mg	Phase 3	Neovascular Age-Related Macular Degeneration	-
aflibercept injection (VEGF Trap-Eye, BAY86-5321)	Phase 3	Macular Degeneration	-
REGN475	Phase 3	Sciatica	-
REGN2810	Phase 3	Non-small Cell Lung Cancer	-
Pembrolizumab	Phase 3	Melanoma	-
Alirocumab	Phase 3	Homozygous Familial Hypercholesterolemia	-
Ezetimibe	Phase 3	Hypercholesterolemia	-
Cyclophosphamide	Phase 3	Follicular Lymphoma (FL)	-
Statin	Phase 3	Hypercholesterolemia	-
REGN5715	Phase 3	Allergic Conjunctivitis	-
Lenalidomide	Phase 3	Relapsed/Refractory Follicular Lymphoma	-
Doxorubicin	Phase 3	Follicular Lymphoma (FL)	-
REGN5714	Phase 3	Allergic Rhinitis	-
Pozelimab + Cemdisiran	Phase 3	Generalized Myasthenia Gravis	-
LMT (atorvastatin, simvastatin, or rosuvastatin)	Phase 3	Heterozygous Familial Hypercholesterolemia	-
Dupilumab	Phase 3	Atopic Dermatitis (AD)	-
REGN7999	Phase 2	Non-Transfusion Dependent Beta-Thalassemia (NTDT)	-
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC	Phase 2	Homozygous Familial Hypercholesterolemia	-
High-dose aflibercept	Phase 2	Neovascular (Wet) Age-Related Macular Degeneration	-
Intravitreal Aflibercept Injection (IAI)	Phase 2	Neovascular Age-Related Macular Degeneration	-
REGN5678	Phase 2	Metastatic Castration-resistant Prostate Cancer	-
REGN10597	Phase 2	Melanoma	-
ISA101b	Phase 2	Cervical Cancer	-
Fixed Dose Combination (FDC) cemiplimab+fianlimab	Phase 2	Melanoma	-
REGN1033 (SAR391786)	Phase 2	Sarcopenia	-
REGN5459	Phase 2	Relapsed Multiple Myeloma	-
BNT116	Phase 2	Advanced Non-Small Cell Lung Cancer	-
Apixaban	Phase 2	Atrial Fibrillation (AF)	-
Enoxaparin	Phase 2	Venous Thromboembolism	-
REGN3918	Phase 2	Paroxysmal Nocturnal Hemoglobinuria (PNH)	-
Tocilizumab	Phase 2	Recurrent Ovarian Cancer	-
ALN-CFB	Phase 2	Paroxysmal Nocturnal Hemoglobinuria (PNH)	-
REGN7075	Phase 2	Advanced Solid Tumors	-
REGN7041	Phase 2	Active Noninfectious Uveitis Affecting the Posterior Segment	-
REGN1908-1909	Phase 2	Cat Allergy	-
REGN2477	Phase 2	Fibrodysplasia Ossificans Progressiva	-
Platinum Doublet	Phase 2	Non-small Cell Lung Cancer	-
REGN5668	Phase 2	Ovarian Cancer	-
Vonsetamig	Phase 2	Chronic Kidney Disease (CKD)	-
REGN5458	Phase 2	Multiple Myeloma	OrphanFast TrackBreakthrough
Timothy Grass SCIT	Phase 2	Allergic Rhinitis	-
REGN5093	Phase 2	NSCLC	-
casirivimab+imdevimab	Phase 2	Healthy	-
Platinum-based chemotherapy	Phase 2	Non-Small Cell Lung Cancer	-
Trevogrumab-Part A	Phase 2	Obesity	-
REGN7544	Phase 2	Postural Orthostatic Tachycardia Syndrome (POTS)	-
VEGF Trap Eye	Phase 2	Macular Degeneration	-
REGN10933+REGN10987 combination therapy	Phase 2	COVID-19	-
REGN910-3	Phase 2	Diabetic Macular Edema	-
PB	Phase 2	Sepsis-Induced Hypotension	-
REGN7945+Linvoseltamab	Phase 2	Relapsed/Refractory Multiple Myeloma	-
Low-Dose REGN4461	Phase 2	Generalized Lipodystrophy	-
Intravitreal Aflibercept Injection	Phase 2	Diabetic Macular Edema	-
REGN5381	Phase 2	Heart Failure	-
ALN-HSD	Phase 2	Metabolic Dysfunction-associated Steatohepatitis (MASH)	-
Ubamatamab	Phase 2	Ovarian Cancer	-
REGN9933	Phase 2	Venous Thromboembolism	-
REGV131	Phase 2	Hemophilia B	-

Regeneron Pharmaceuticals, Inc.

Market Overview

REGN7544 Phase 2 Results Expected

Sarilumab Phase 2 Results Expected

Tocilizumab Phase 2 Results Expected

Cemiplimab Phase 2 Results Expected

Placebo Phase 2 Results Expected

Cemiplimab Phase 3 Results Expected

Fianlimab Phase 3 Results Expected

Placebo Phase 3 Results Expected

Pembrolizumab Phase 3 Results Expected

Carboplatin Phase 2 Results Expected

Cemiplimab Phase 2 Results Expected

Pemetrexed Phase 2 Results Expected

Placebo Phase 2 Results Expected

Fianlimab Phase 2 Results Expected

Trevogrumab-Part A Phase 2 Results Expected

Garetosmab Phase 2 Results Expected

REGN9933 Phase 2 Results Expected

REGN7508 Phase 2 Results Expected

Placebo Phase 2 Results Expected

Odronextamab Phase 2 Results Expected

mibavademab Phase 3 Results Expected

PB Phase 2 Results Expected

REGN7544 Phase 2 Results Expected

REGN7075 Phase 2 Results Expected

Dupilumab Phase 3 Results Expected

Placebo Phase 3 Results Expected

Cemiplimab Phase 3 Results Expected

Sarilumab Phase 2 Results Expected

REGN5678 Phase 2 Results Expected

Cemiplimab Phase 2 Results Expected

AI Predictions & Institutional Flow

FDA Submissions

Drug Pipeline

Regulatory & News

Regeneron Pharmaceuticals, Inc.

Market Overview

REGN7544 Phase 2 Results Expected

Sarilumab Phase 2 Results Expected

Tocilizumab Phase 2 Results Expected

Cemiplimab Phase 2 Results Expected

Placebo Phase 2 Results Expected

Cemiplimab Phase 3 Results Expected

Fianlimab Phase 3 Results Expected

Placebo Phase 3 Results Expected

Pembrolizumab Phase 3 Results Expected

Carboplatin Phase 2 Results Expected

Cemiplimab Phase 2 Results Expected

Pemetrexed Phase 2 Results Expected

Placebo Phase 2 Results Expected

Fianlimab Phase 2 Results Expected

Trevogrumab-Part A Phase 2 Results Expected

Garetosmab Phase 2 Results Expected

REGN9933 Phase 2 Results Expected

REGN7508 Phase 2 Results Expected

Placebo Phase 2 Results Expected

Odronextamab Phase 2 Results Expected

mibavademab Phase 3 Results Expected

PB Phase 2 Results Expected

REGN7544 Phase 2 Results Expected

REGN7075 Phase 2 Results Expected

Dupilumab Phase 3 Results Expected

Placebo Phase 3 Results Expected

Cemiplimab Phase 3 Results Expected

Sarilumab Phase 2 Results Expected

REGN5678 Phase 2 Results Expected

Cemiplimab Phase 2 Results Expected

AI Predictions & Institutional Flow

FDA Submissions

Drug Pipeline

Regulatory & News